OCTS (Onco Cell Therapy) | Kisaco Research

Revolutionising patient outcomes in cancer therapies

OCTS Global: Register Today!

FREE WEBINAR: ASH Review | 15th Dec 2020

2nd Annual NK Day | 19th Jan 2021

INVESTOR FORUM | 22nd Jan 2021

About the OCTS Portfolio

Immuno-oncology is emerging as the 5th pillar of oncology. Remarkable therapy efficacies have been shown as the active use of CAR-T therapies in healthcare services around the world has forged the way for the next generation of cancer treatment to arrive.

OCTS addresses the future hurdles for cell therapies in immuno-oncology to revolutionize patient outcomes in cancer treatment. By driving down cost through more efficient scalable and automated vein to vein processes, and increasing efficacies and lowering toxicities in the next generation of cell therapies, OCTS is driving towards more accessible cell therapies worldwide.

Filter by:
23 Mar 2021
Cancer immunology is establishing itself as the 5th pillar of oncology. T cell Therapies hitting the market have shown remarkable success, but their full potential is yet to be delineated. With patient responses limited in CAR-T treatment of solid tumors, the role of macrophages within the tumor microenvironment has come under increased scrutiny.The Macrophage Therapy Symposium will outline the key approaches for macrophage stimulation to limit immune suppression, angiogenesis and the resultant resistance to immune therapy.Join us on March 23 with key academics, innovative biotechs and pioneering pharmaceutical companies to meet and unpack the mechanisms and paradigms surrounding the key targets for macrophage modulation.
16-17 Nov 2021
Boston, USA
The world shut down in 2020 as the pandemic had a global impact on trade and development, but the onco cell therapy industry remained resilient in the face of all of this. In spite of 69% of industry claiming that their biggest challenges in 2020 was meeting their projected timelines for their pipes, the race for bringing the first BCMA targeting CAR-T to the market is reaching a climax and next-generation cell therapies are at the front of mind for those in both industry and research.Significant break throughs in GvHD for allogeneic treatments and in the use of alternative cell therapies mean that onco cell therapies are embedding themselves as the 5th pillar of oncology. New combination studies and manufacturing capabilities are showing even more promise for this sector, but with current treatments still having high costs of use and as there are limited patient pools, there are still challenges in both clinical and commercial use of these therapies.The Onco Cell Therapy Summit (OCTS), November 17 - 18, Boston USA, brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to the process of translating R&D into commercially viable oncological therapies.We’ve worked with industry partners to ensure that OCTS 2021 is dedicated to the effective translation and commercialization of research into safe and efficacious therapies and address these challenges.
Filter by:
20-21 Jan 2021
Following the success of our first digital event in July with the likes of Carl June leading the keynote, the Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations, townhall meetings, roundtable sessions and coffee break style networking.The Global Onco Cell Therapy Summit is an online event, January 19th - 21st, that provides a platform for information sharing to enable the discovery, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma, biotechs and academia. The summit will address the research, regulatory, logistical and technical challenges that are holding back the field.Delve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through:Meeting efficacies and safety targets as well as the scale of demands.Discovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.Overcoming the challenging in scale up and automation of manufacturingRound table discussions on vectors and the promise of non-viral approaches.Reimbursment strategies and their link to the latest developments in safety trials and regulatory standards Whilst bringing together the key decision makers for oncological cell therapies, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments.

Our Network

Partnership Opportunities

— OCTS (Onco Cell Therapy) Partners Include —


The OCTS portfolio is your global, multi-channel partner to reach, engage and interact with the most influential and important stakeholders in the world of Cell & Gene Therapy.

With a solution to hit every objective, our high-level annual summits, bespoke introductions, reports, webinars and content-driven marketing offer multiple ways engage your target market and can form an integral part of your annual marketing plan.
At Kisaco, we also know that you need different solutions at different times of the year, so our packages can be built to order to fit in with your current plans.

  • Product launch? – If you need to bring a new product to market, you’ll need air-time to make announcements, synchronized marketing and PR announcements to leverage our audiences and media partnerships, as well as access to client accounts to build sales pipelines. We can help!
  • Need to drive leads? Our summits offer best-in-class networking opportunities, giving you access to decision makers to arrange meetings, while our bespoke webinars offer up a chance to get hundreds of leads in one single activity.
  • Want thought leadership? Showcase your expertise by presenting on market-leading programs .
  • Need investment? – Regardless of where you are in your fund-raising journey, we have can help give you the visibility and platform you need to put you in the eyeline of the investor.

Talk to us today to see how we can give you access to the decision makers you need and look at a short, mid or long term marketing plan. E: [email protected]

Partner with Us